Maybe a really dumb question for @RaceOncology which I probably should had asked earlier on (many months ago).
Why is the FTO study / Pillar 1 focused on melanoma? Is this because PD-1 is highest and promotes cancer cell growth most in melanoma? Then once identified whether it is effective in this area, it could be expanded to other similar cancers where the FTO protein is high, i.e., lung and breast?
Sorry if this has been covered off before, just so much to get through some days that I miss some of the technical stuff (goes over the top of my head)...
Ann: Race Initiates FTO Melanoma Preclinical Study, page-19
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |